2023 Q3 Form 10-Q Financial Statement

#000168316823005930 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $17.35K $22.21K $6.925K
YoY Change -67.14% 220.65%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $17.35K $22.21K $6.925K
YoY Change -67.14% 220.65%
Operating Profit -$17.35K -$22.21K -$6.925K
YoY Change -67.14% 220.65%
Interest Expense $10.68K $8.490K $3.364K
YoY Change 164.58% 152.38%
% of Operating Profit
Other Income/Expense, Net -$10.68K -$8.490K -$3.364K
YoY Change 164.58% 152.38%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$28.03K -$30.70K -$10.29K
YoY Change -50.68% 198.33% -48.27%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01 $0.00
Diluted Earnings Per Share -$0.01 -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 3.046M shares 140.8M shares 3.046M shares
Diluted Shares Outstanding 3.046M shares 3.046M shares 3.046M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $3.934K $5.112K $19.58K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.934K $5.112K
YoY Change 9.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.934K $5.112K
Total Long-Term Assets $0.00 $0.00
Total Assets $3.934K $5.112K
YoY Change 9.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.200K $11.03K
YoY Change
Accrued Expenses $33.49K $33.49K
YoY Change 0.0%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $226.1K $199.3K
YoY Change 65.87%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $226.1K $199.3K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$1.023M -$994.9K
YoY Change 9.58%
Common Stock $30.00 $30.00
YoY Change -97.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$222.2K -$194.2K -$75.91K
YoY Change
Total Liabilities & Shareholders Equity $3.934K $5.112K
YoY Change 9.34%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$28.03K -$30.70K -$10.29K
YoY Change -50.68% 198.33% -48.27%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001945619
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56478
dei Entity Registrant Name
EntityRegistrantName
BELLATORA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1981170
dei Entity Address Address Line1
EntityAddressAddressLine1
2030 Powers Ferry Rd. SE
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite #212
dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30339
dei City Area Code
CityAreaCode
404
dei Local Phone Number
LocalPhoneNumber
816-8240
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3046000 shares
CY2023Q2 us-gaap Cash
Cash
5112 usd
CY2022Q4 us-gaap Cash
Cash
1376 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
5112 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1376 usd
CY2023Q2 us-gaap Assets
Assets
5112 usd
CY2022Q4 us-gaap Assets
Assets
1376 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
11032 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12366 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
34760 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
21674 usd
CY2023Q2 ECGR Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
120000 usd
CY2022Q4 ECGR Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
90000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
199278 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
157526 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3046000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3046000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3046000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3046000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
30 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
800656 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
800656 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-994852 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-956835 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-194166 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-156149 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5112 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1376 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3046000 shares
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22205 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6925 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24931 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8275 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
22205 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
6925 usd
us-gaap Operating Expenses
OperatingExpenses
24931 usd
us-gaap Operating Expenses
OperatingExpenses
8275 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22205 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6925 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-24931 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8275 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
8490 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
3364 usd
us-gaap Interest Expense
InterestExpense
13086 usd
us-gaap Interest Expense
InterestExpense
5612 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8490 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3364 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13086 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5612 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-30695 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10289 usd
us-gaap Net Income Loss
NetIncomeLoss
-38017 usd
us-gaap Net Income Loss
NetIncomeLoss
-13887 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3046000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3046000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3046000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3046000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3046000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3046000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3046000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-62018 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3598 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-65616 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10289 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-75905 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-156149 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7322 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-163471 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-30695 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-194166 usd
us-gaap Net Income Loss
NetIncomeLoss
-38017 usd
us-gaap Net Income Loss
NetIncomeLoss
-13887 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1334 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
13086 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
8807 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26264 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5080 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
30000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
20000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3736 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14920 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1376 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4663 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5112 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19583 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zdGOTjgpfzK" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of accrued liabilities and expenses during the reporting period. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-994852 usd
CY2023Q2 ECGR Working Capital
WorkingCapital
-194166 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3046000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3046000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3046000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3046000 shares
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse split of 1 for 100

Files In Submission

Name View Source Status
0001683168-23-005930-index-headers.html Edgar Link pending
0001683168-23-005930-index.html Edgar Link pending
0001683168-23-005930.txt Edgar Link pending
0001683168-23-005930-xbrl.zip Edgar Link pending
bellatora_ex3101.htm Edgar Link pending
bellatora_ex3201.htm Edgar Link pending
bellatora_i10q-063023.htm Edgar Link pending
ecgr-20230630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ecgr-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ecgr-20230630_def.xml Edgar Link unprocessable
ecgr-20230630_pre.xml Edgar Link unprocessable
ecgr-20230630_lab.xml Edgar Link unprocessable
bellatora_i10q-063023_htm.xml Edgar Link completed